Biojo Statement on Novel Coronavirus (COVID-19)
In a time of uncertainty, Biojo Sciences is dedicated to ensuring the safety of our team, partners, and stakeholders. As we monitor the the pandemic, please remember to practice social distancing, wash hands often, and follow the appropriate guidelines from your nation’s health professionals. Here are some available resources, including a case map from our colleagues at Johns Hopkins. We also wanted to take this opportunity to remind those in the biopharmaceutical industry that there is still the need to develop much needed life-improving and life-saving therapies. With most of us working from home, we wanted to remind you Biojo Sciences is open to electronic communication and meetings. Contact us today
- Johns Hopkins University map of Coronavirus COVID-19 global cases
- U.S. Official Coronavirus (COVID-19) website
- U.S. Center for Disease Control and Prevention (CDC)
- U.S. Department of Health & Human Services (HHS)
- World Health Organization
About Biojo Sciences
Biojo Sciences is a global biopharmaceutical company developing novel clinical-stage therapies that improve patient and family lives. Our approach offers an efficient development process by finding and delivering innovative clinical-stage biotechnologies through effective operations and an NRDO, non-research development only model. We invest in bringing early-stage drug assets to commercialization.
